TERN - Terns Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

362.7M

Cash

297.5M

Avg Qtr Burn

-12.55M

Short % of Float

8.49%

Insider Ownership

2.10%

Institutional Own.

93.61%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TERN-501 (THR-B Agonist) +TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-201 (VAP-1 inhibitor) Details Non-alcoholic steatohepatitis	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-601 (Oral GLP-1R Agonist Details Obesity	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-701 (Allosteric BCR-ABL inhib) Details Chronic myelomonocytic leukemia	Phase 1 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.